Top

International Urogynecology Journal

Published in:

01-07-2012 | Original Article

The role of serum C-reactive protein in women with lower urinary tract symptoms

Authors: Sheng-Mou Hsiao, Ho-Hsiung Lin, Hann-Chorng Kuo

Published in: International Urogynecology Journal | Issue 7/2012

Abstract

Introduction and hypothesis

Some lower urinary tract dysfunction (LUTD) subtypes may be associated with low-grade inflammation. This study aimed to investigate the role of serum C-reactive protein (CRP) levels in women with lower urinary tract symptoms (LUTS).

Methods

A total of 197 consecutive women with non-stress urinary incontinence (non-SUI) LUTS and 18 healthy women without LUTS (normal controls) were enrolled. LUTS include urinary storage, voiding, and post-micturition symptoms. Patients with previous bladder or urethral surgery, active urinary tract infections, or possible neurogenic lesions were excluded. Serum CRP levels were measured before any treatment was given. Patients were stratified to LUTD subgroups based on a 3-day voiding diary, uroflowmetry, and selective videourodynamic studies.

Results

Median CRP levels were significantly higher in women with overactive bladder (OAB) wet (i.e., with urgency incontinence, n = 30, 0.12 mg/dl) than those in women with bladder oversensitivity (n = 68, 0.075 mg/dl, P = 0.008) and the control group (0.055 mg/dl, P = 0.032). Further analysis revealed that body mass index and maximum flow rate were two independent factors that affected CRP levels. The area under the receiver-operating characteristic curve for using CRP to predict OAB wet was 0.55, and the most predictive cutoff point for CRP was 0.15 mg/dl (sensitivity 43.5 %, specificity 72.7 %).

Conclusions

High serum CRP levels were found in women with OAB wet, and they were related to lower maximum urinary flow rates and higher body mass indices in non-SUI LUTD. However, serum CRP is not a suitable biomarker for discriminating between subtypes of non-SUI LUTD.

Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5–26PubMedCrossRef

Hung MJ, Ho ES, Shen PS et al (2006) Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis. J Urol 176:636–640PubMedCrossRef

Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543–562PubMedCrossRef

Tyagi P, Barclay D, Zamora R et al (2010) Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 42:629–635PubMedCrossRef

Khasriya R, Khan S, Lunawat R et al (2010) The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. J Urol 183:1843–1847PubMedCrossRef

Cartwright R, Afshan I, Derpapas A, Vijaya G, Khullar V (2011) Novel biomarkers for overactive bladder. Nat Rev Urol 8:139–145PubMedCrossRef

Antunes-Lopes T, Pinto R, Carvalho-Barros S et al (2011) Urinary levels of brain derived neurotrophic factor (BDNF) in women with overactive bladder (OAB) syndrome correlate with the severity of symptoms. Eur Urol Suppl 10:277–278CrossRef

Liu HT, Tyagi P, Chancellor MB, Kuo HC (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106:1681–1685PubMedCrossRef

Kushner I (1982) The phenomenon of the acute phase response. Ann N Y Acad Sci 389:39–48PubMedCrossRef

10.

Chung SD, Liu HT, Lin H, Kuo HC (2011) Elevation of serum C-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn 30:417–420PubMedCrossRef

11.

Kupelian V, McVary KT, Barry MJ et al (2009) Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey. Urology 73:950–957PubMedCrossRef

12.

St Sauver JL, Sarma AV, Jacobson DJ et al (2009) Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 169:1281–1290PubMedCrossRef

13.

Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 68:318–323PubMedCrossRef

14.

Nixon A, Colman S, Sabounjian L et al (2005) A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174:604–607PubMedCrossRef

15.

Chung SD, Liao CH, Chen YC, Kuo HC (2011) Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. Neurourol Urodyn 30:1300–1304PubMed

16.

Kuo HC (2005) Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction. Urology 66:1005–1009PubMedCrossRef

17.

Kuo YC, Kuo HC (2012) Potential factors that can be used to differentiate between interstitial cystitis/painful bladder syndrome and bladder oversensitivity in women. Int J Clin Pract 66:146–151. doi:10.1111/j.1742-1241.2011.02767.x

18.

Altman DG (1991) Relation between several variables. In: Altman DG (ed) Practical statistics for medical research. Chapman & Hall, London, pp 325–364

19.

Chuang YC, Tyagi V, Liu RT, Chancellor MB, Tyagi P (2010) Urine and serum C-reactive protein levels as potential biomarkers of lower urinary tract symptoms. Urol Sci 21:132–136CrossRef

20.

Compérat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E (2006) Histologic features in the urinary bladder wall affected from neurogenic overactivity—a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 50:1058–1064PubMedCrossRef

21.

Apostolidis A, Jacques TS, Freeman A et al (2008) Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53:1245–1253PubMedCrossRef

22.

Jang J, Park EY, Seo SI, Hwang TK, Kim JC (2006) Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 98:435–439PubMedCrossRef

23.

Dmitrieva N, McMahon SB (1996) Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 66:87–97PubMedCrossRef

24.

Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813–1818PubMedCrossRef

25.

Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511PubMedCrossRef

26.

Wee CC, Mukamal KJ, Huang A, Davis RB, McCarthy EP, Mittleman MA (2008) Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring) 16:875–880CrossRef

27.

Hwang JJ, Li HY, Shieh GJ, Chien YF, Hua CH, Lin JW (2008) Illustrating the roles of C-reactive protein in the development of the metabolic syndrome in women—a cross-racial validation. Nutr Metab Cardiovasc Dis 18:671–677PubMedCrossRef

28.

Aronson D, Bartha P, Zinder O et al (2004) Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 28:674–679PubMedCrossRef

29.

Khera A, McGuire DK, Murphy SA et al (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46:464–469PubMedCrossRef

30.

Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349:462–466PubMedCrossRef

Title: The role of serum C-reactive protein in women with lower urinary tract symptoms
Authors: Sheng-Mou Hsiao
Ho-Hsiung Lin
Hann-Chorng Kuo
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 7/2012
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-012-1715-1

At a glance: The STEP trials

Springer Medicine

The role of serum C-reactive protein in women with lower urinary tract symptoms

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2012

Women with occult stress incontinence should not routinely have a mid-urethral sling with prolapse surgery

Incontinence during intercourse: myths unravelled: reply to Serati et al.

Do urodynamic parameters predict persistent postoperative stress incontinence after midurethral sling? A systematic review

Effectiveness of midurethral slings in recurrent stress urinary incontinence: a systematic review and meta-analysis

Modified laparoscopic extraperitoneal uterine suspension to anterior abdominal wall: the easier way to treat uterine prolapse

Sacrohysteropexy followed by successful pregnancy and eventual reoperation for prolapse